Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q2 2019 · 10-Q
Revenue$0.00$0.00derived−100.0% vs Q2 2018 Net Income-$18.02M-$18.02MN/M vs Q2 2018 EPS Diluted-$0.55-$0.55N/M vs Q2 2018 Operating Income-$18,622,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
Operating Cash Flowderived-$16,383,000N/M Free Cash Flowderived-$16,440,000N/M ended Jun 30, 2019 · filed Aug 6, 2019 · 37 d after period end